Spastic ataxia Charlevoix–Saguenay type

Spastic ataxia Charlevoix–Saguenay type (SACS), also known as Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), is a rare, genetically inherited condition characterized by a combination of spasticity and ataxia. This neurodegenerative disorder was first identified in the Charlevoix–Saguenay region of Quebec, Canada, hence its name. It is caused by mutations in the SACS gene, which encodes the sacsin protein, playing a crucial role in the maintenance and function of neurons in the central nervous system.

Symptoms and Diagnosis

The symptoms of SACS typically begin in early childhood and may include difficulty with movement and coordination, muscle stiffness (spasticity), and a loss of fine motor skills. As the condition progresses, individuals may also experience nystagmus (involuntary eye movement), dysarthria (difficulty in articulating words), and sensory neuropathy. Diagnosis of SACS is based on clinical examination, family history, and genetic testing to identify mutations in the SACS gene.

Genetics

SACS is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutation, typically do not show symptoms of the disease.

Treatment and Management

There is currently no cure for SACS, and treatment focuses on managing symptoms and improving quality of life. This may include physical therapy to enhance mobility and prevent contractures, occupational therapy to assist with daily activities, and speech therapy to address communication difficulties. In some cases, medications may be prescribed to alleviate specific symptoms such as spasticity.

Epidemiology

While SACS was initially thought to be confined to the Charlevoix–Saguenay region, cases have since been identified worldwide, indicating a broader distribution of the genetic mutation responsible for the disorder. However, it remains a rare condition, with a higher prevalence in populations with a history of French-Canadian ancestry due to a founder effect.

Research

Research into SACS is ongoing, with studies focusing on understanding the function of the sacsin protein, the pathogenesis of the disorder, and the development of potential therapeutic strategies. Gene therapy and molecular treatments targeting the underlying genetic defects hold promise for future interventions.

Spastic ataxia Charlevoix–Saguenay type Resources
Latest articles Most recent articles Ongoing trials	Wikipedia